B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma
β Scribed by Scott J. Antonia; John D. Seigne
- Publisher
- Springer-Verlag
- Year
- 2000
- Tongue
- English
- Weight
- 92 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
87-I (CD80) provides co-stimulation for T-cell activation by interacting with CD28 or CTLA4. Here we demonstrate the expression of 87-I in freshly isolated and cultured lymphocytes from renal-cell carcinoma. In fresh preparations of lymphocytes infiltrating renal-cell-carcinoma tissue, B7-I mRNA cou
## Abstract Although the existence of a humoral response against tumorβassociated antigens is well appreciated, a systematic analysis of its possible induction by the tumor remains missing. We compared the specific IgG response of Stage IV melanoma patients during vaccination. Patients had been tre
Vaccination with tumour cells genetically modified to support induction of an immune response either by production of cytokines or expression of co-stimulatory molecules provides a promising therapeutic approach. We have evaluated the efficiency of tumour vaccination using RENCA cells, a renal cell
## Abstract Renal clear cell carcinoma (RCCC) is a malignant tumor with poor prognosis caused by the high incidence of metastasis to distal organs. Although metastatic RCCC cells frequently show aberrant cytoskeletal organization, the underlying mechanism has not been elucidated. DALβ1/4.1B is an a